An Exploratory Study of MT-2990 in Patients With AAV

NCT ID: NCT06196905

Last Updated: 2026-02-04

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE1
• Total Enrollment: 5 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2024-06-24
• Study Completion Date: 2026-01-14

Brief Summary

To explore the efficacy, safety, pharmacokinetics and mechanism of action of MT-2990 in patients with AAV.

Detailed Description

Target sample size is 5~10 subjects administered MT-2990

Conditions

Antineutrophil Cytoplasmic Antibody (ANCA) -Associated Vasculitis (AAV)

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

MT-2990

MT-2990 will be administered intravenously every 4 weeks for a total of 6 doses.

Group Type: EXPERIMENTAL

MT-2990

Intervention Type: DRUG

i.v. infusion

Interventions

MT-2990

i.v. infusion

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

1. Patients aged 18 years or older on the day of informed consent

2. Clinical diagnosis of microscopic polyangiitis (MPA), granulomatosis with polyangiitis (GPA), or eosinophilic granulomatosis with polyangiitis (EGPA) according to 2022 ACR/EULAR Classification Criteria by the date of informed consent

3. Patients who meet at least one of the following criteria 1) or 2)

1) Patients is judged to be indicative of disease activity by the investigator with disease activity satisfying all of the following criteria at screening. If measurements or tests were performed multiple times during the screening period, the results from the latest date should be used to confirm that the criteria are met.

I. As elevated CRP due to active AAV, CRP >= 0.2 mg/dL

II. BVAS >= 1

III. At least one of the findings in a) to e) below. c) is only applicable to patients with EGPA.

1. FDG-PET/CT image finding(s) (Grade >= 2 [defined as FDG uptake = liver], and judged that the findings indicate inflammation by radiologist)

2. FVC(mL) below the lower limit of normal calculated using the "new reference range for Japanese using LMS method" and KL-6 >= 500 U/mL

3. History or presence of asthma and eosinophils counts >= 1000/µL

4. eGFR < 60 mL/min/1.73 m 2 and first-morning urine protein/creatinine ratio > 0.2 g/g Cr

5. Presence of hearing loss due to active AAV and air conduction hearing threshold (average of measurements at 0.25,0.5,1, 2, and 4 kHz) >= 30 dB in at least one ear

2) Steroid-dependent patients who satisfy the following criteria I and II:

II. No initiation or increased dose of azathioprine or avacopan since the time of the worsening of the primary disease of I.

Exclusion Criteria

1. Patients who have manifestations leading to life-threatening or vital organ dysfunction due to AAV, in the opinion of the Investigator.

2. Patients with autoimmune diseases or vasculitis other than AAV such as systemic lupus erythematosus, IgA vasculitis, rheumatoid vasculitis, Sjogren's syndrome, anti-glomerular basement membrane nephritis, cryoglobulinemic vasculitis, idiopathic inflammatory muscle disease, systemic sclerosis.

3. Patients who are judged by the Investigator to have an improvement trend of active finding(s) for AAV during remission maintenance treatment from the 12 weeks prior to the start of screening to the time of the first dose, and to be expected to improve spontaneously without change of treatment.

4. Patients who received rituximab or immunosuppressive biologics (eg., TNF inhibitors) from 12 weeks prior to the start of screening to the time of the first dose.

5. Patients who received mepolizumab from 8 weeks prior to the start of screening to the time of the first dose.

6. Patients who received cyclophosphamide, methotrexate, mycophenolate mofetil, plasma exchange therapy or other immunosuppressive therapy from 4 weeks prior to screening to the time of the first dose.

7. Patients who received a live vaccine from 4 weeks before the date of the first dose to the time of the first dose.

8. Patients who have received steroids at prednisolone equivalent doses of more than 20 mg/day, initiated steroids, or increased the dose of steroids from 4 weeks prior to the start of screening to the time of the first dose.

Exceptionally, only for rituximab treatment failures are allowed to initiate steroids or increase steroids dose up to that of their most recent induction remission therapy (i.e., doses exceeding 20 mg/day of prednisolone equivalent are allowed) until the day before the first dose.

9. Patients who have initiated, increased, or decreased the dose of azathioprine from 4 weeks prior to the start of screening to the time of the first dose.

10. Patients who have initiated, increased, or decreased the dose of avacopan from 4 weeks prior to the start of screening to the time of the first dose.

11. Patients with concomitant or history of hepatitis B virus (HBV), hepatitis C virus (HCV), or human immunodeficiency virus (HIV) infection unless patients have negative test result of hepatitis B virus surface (HBs) antigen, HBs antibody, and hepatitis B virus core (HBc) antibody at screening, or have maintained a negative HCV-RNA test result for at least 12 weeks after completion of hepatitis C treatment.

12. Patients with systemic active infections at the day of screening evaluation or the date of the first dose.

13. Patients with a history of malignancy within 5 years prior to the start of screening, except for basal cell carcinoma of the skin, squamous cell carcinoma of the skin, or intraepithelial carcinoma of the cervix who have completed treatment (including therapy other than anticancer agents for the treatment of cancer) without recurrence for at least 1 year.

14. History of anaphylaxis or clinically significant allergic symptoms due to administration of antibody products.

15. Patients who have received anti-IL-33 antibodies including this investigational drug in the past.

16. Patients with serious complications.

17. Male and female patients of childbearing potential (Excluding postmenopausal women who have been amenorrheic for at least 1 year and women who have undergone surgical hysterectomy or bilateral oophorectomy) who are unable to obtain consent to use contraception from the date of consent until 12 weeks after completion of study drug administration.

18. Female patients who are pregnant, breastfeeding, or possibly pregnant

19. Patients who participated in any clinical trial and received the investigational medical product within 12 weeks (or 5 half-lives of investigational medical product, whichever is longer) prior to obtaining consent.

20. Patients who are judged by the Investigator to be ineligible for this clinical trial.

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Tanabe Pharma Corporation

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

General Manager

Role: STUDY_DIRECTOR

Tanabe Pharma Corporation

Locations

Hiroshima University Hospital

Hiroshima, Hiroshima, Japan

Kagawa University Hospital

Kita-gun, Kagawa-ken, Japan

Saitama Medical University Hospital

Iruma-gun, Saitama, Japan

Saitama Medical Center

Kawagoe, Saitama, Japan

Juntendo University Hospital

Bunkyo-ku, Tokyo, Japan

NHO Tokyo Medical Center

Meguro-ku, Tokyo, Japan

Kyorin University Hospital

Mitaka-shi, Tokyo, Japan

Keio University Hospital

Shinjuku-ku, Tokyo, Japan

Countries

Japan

Other Identifiers

jRCT2031230538

Identifier Type: OTHER

Identifier Source: secondary_id

MT-2990-C-101

Identifier Type: -

Identifier Source: org_study_id